Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Progress in Wholly-owned Subsidiary’s Clinical Trial for VUM02 Injection
Filed with SSE · · 3 pages · Chinese
On 6ix: 6ix.com/news/announcement-on-progress-in-wholly-owned-subsidiarys-clinical-trial-for-vum02-injection
Release
Vcanbio Cell & Gene Engineering Corp., Ltd. on 6ix
Earlier from Vcanbio Cell & Gene Engineering
- Announcement on Progress in Using Temporarily Idle Raised Funds for Cash Management
- Announcement on Redemption of Idle Raised Funds Used for Cash Management upon Maturity
- Announcement on Subsidiary’s Receipt of a Medical Device Registration Certificate
- with the University of Chinese Academy of Sciences Education Foundation and the Progress in Hosting the Vcanbio Life Sciences Award
- Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
Later from Vcanbio Cell & Gene Engineering
- Announcement on 2025 Annual Profit Distribution Plan
- Indicative Announcement on Convening the 2025 Annual General Meeting
- Announcement on Return of Raised Funds Temporarily Used to Supplement Current Capital
- Announcement on Resolutions of the 2025 Annual General Meeting
- Announcement on Convening the 2025 Annual Performance Briefing
Follow Vcanbio Cell & Gene Engineering into a list and get an email when it puts out news.
Follow Vcanbio Cell & Gene Engineering